Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
662 people get UTHR articles and Market Currents by email alert.
Get email alerts on UTHR »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
PR Newswire (Apr 25, 2013)
-
-
-
-
-
-
PR Newswire (Mar 25, 2013)
-
-
-
-
-
PR Newswire (Feb 26, 2013)
To learn more about Seeking Alpha Pro, click here.
-
-
United Therapeutics: Estimates On An UpswingZacks Investment Research • Mon, Oct 15, 2012 -
-
4 Reasons To Buy United TherapeuticsMarkus Aarnio • Tue, Jun 5, 2012
-
-
-
-
-
United Therapeutics Swings to Profit in Q4Proactive Investor • Wed, Feb 16, 2011 -
-
United Therapeutics Corporation Special CallWed, Aug 24, 2011
-
United Therapeutics Corporation Q4 2009 Earnings Call TranscriptTue, Feb 16, 2010
-
United Therapeutics Corp. Q2 2009 Earnings Call TranscriptFri, Jul 31, 2009
-
United Therapeutics Corporation Q4 2008 Earnings Call TranscriptTue, Feb 17, 2009
-
United Therapeutics Corporation Q2 2008 Earnings Call TranscriptThu, Jul 31, 2008
-
United Therapeutics Corp. Q1 2008 Earnings Call TranscriptFri, May 2, 2008
-
United Therapeutics Corp. Q4 2007 Earnings Call TranscriptTue, Feb 19, 2008
-
at MarketWatch.com (Apr 30, 2013)
-
PR Newswire (Apr 25, 2013)
-
PR Newswire (Mar 25, 2013)
-
PR Newswire (Feb 26, 2013)
-
PR Newswire (Feb 14, 2013)
-
PR Newswire (Feb 4, 2013)
-
PR Newswire (Nov 1, 2012)
-
at MarketWatch.com (Oct 24, 2012)
-
PR Newswire (Oct 23, 2012)
-
at CNBC.com (Oct 10, 2012)
-
at MarketWatch.com (Sep 25, 2012)
-
at Fox Business (Aug 15, 2012)
-
PR Newswire (Jul 26, 2012)
-
PR Newswire (Jun 27, 2012)
-
PR Newswire (Apr 26, 2012)
UTHR vs. ETF Alternatives
Company Description
We are a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions.
Our key therapeutic platforms are:
Prostacyclin Analogues, which are stable synthetic... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Thursday, April 25, 3:46 PM United Therapeutics (UTHR -3%) slides after its Q1 EPS results missed Street expectations earlier today. Revenue increased by nearly $41M over the prior year the period, with growth in product revenues reflecting the continuing increase in the number of patients being treated, but expenses in both R&D and SG&A pressured bottom line performance. Comment! [Healthcare, Earnings, On the Move]
- Thursday, April 11, 11:15 AM United Therapeutics (UTHR +0.1%) says it's received approval to perform a human Phase I study in Australia using Pluristem Therapeutics' (PSTI +1.6%) PLacental eXpanded cells in patients diagnosed with Pulmonary Arterial Hypertension. United Therapeutics and Pluristem entered into a licensing agreement in 2011 that allows UTHR to develop, market and sell PSTI's PLX-PAD cells. 1 Comment [Healthcare, On the Move]
- Monday, March 25, 9:10 AM Premarket gainers: ZAZA +21%. ARWR +14%. APOL +9%. TSRX +5%. Losers: IDIX -10%. OTT -10%. UTHR -7%. PGTI -6%. Comment! [On the Move]
- Monday, March 25, 6:11 AM The FDA has again rejected United Therapeutics' (UTHR) Treprostinil oral treatment for treating for high blood pressure. United Therapeutics intends to immediately request an "end of review" meeting with the FDA to discuss the rejection. Shares -6.3% premarket. (previous) (PR) Comment! [On the Move, Healthcare]
- Tuesday, February 26, 1:26 PM After a valliant fight, United Therapeutics (UTHR -0.9%) gives up the days gains to trade in the red after Brean Murray cuts the shares to Hold on the back of its Q4 results posted earlier. The stock has had a good run since plummeting in October of last year on the FDA's rejection of Treprostinil, gaining nearly 30% and presently testing a 2-year high. Comment! [Healthcare, On the Move]
- Monday, February 4, 11:17 AM United Therapeutics (UTHR +1.3%) moves up after its board authorizes an additional $420M to its existing share repurchase program. The program will become effective on March 4 and remain open for up to one year. Separately, Standpoint Research ups the shares from Hold to Buy. Comment! [Healthcare, On the Move]
- Wednesday, October 24, 2012, 12:45 PM Midday top 10 gainers: SEH +61%. KIPS +25%. CHC +21%. FB +21%. LL +15%. PLCM +14%. ASPS +11%. DHX +12%. MNST +13%. CYCC +12%. Top 10 Losers: TPX -22%. IRBT -19%. CPWR -16%. UIS -15%. NFLX -14%. DSCO -14%. UTHR -13%. BWLD -12%. NSM -12%. NFX -12%. Comment! [On the Move]
-
Wednesday, October 24, 2012, 9:10 AM
Premarket gainers: SEH +62%. FB +26%. RFMD +14%. LL +13%. RENN +11%. POL +10%. DOW +6%. ZNGA +5%. GRPN +5%. MM +6%.
Losers: TPX -21%. NFLX -18%. DSCO -14%. UTHR -12%. INVN -8%. KMT -7%. XOMA -7%. Comment! [On the Move] - Wednesday, October 24, 2012, 8:25 AM United Therapeutics (UTHR) dives 11.8% after yesterday saying that the FDA has turned down the company's new drug application for treprostinil, an oral treatment for high blood pressure. The agency is uncertain whether another study would help change its mind, but said that if UTHR does decide on a further trial, it should consider a fixed dose design and more frequent dosing. (PR) 1 Comment [Healthcare, On the Move]
-
Tuesday, October 23, 2012, 5:40 PM
After-hours top gainers, as of 5:15 p.m.: RFMD +12%; TWIN +9.2%; FB +8.2%; IDIX +6.5%; PNRA +6.4%.
After-hours top losers: INVN -19.1%; TPX -18.4%; IRBT -15.2%; BWLD -10.2%; UTHR -9.9%. 1 Comment [On the Move] - Thursday, April 12, 2012, 11:33 AM United Therapeutics (UTHR -2.6%) shares are downgraded to Market Perform from Outperform with a new price target of $48 from $65 by Leerink Swann, which cites generic risk to its treatment of pulmonary arterial hypertension. A recent survey by the firm says "most physicians believe that a minority of their patients are candidates for oral Remodulin." Comment! [Healthcare, On the Move]
- Tuesday, March 20, 2012, 3:49 PM Argus lines up United Therapeutics (UTHR -1.4%) as an undervalued name in the healthcare sector, as it maintains a Buy rating on the biotech concern. Analysts with the firm expect Argus to hit its 2012 sales target, as they raise their price target on shares by $8 to $60. Comment! [On the Move, Healthcare]
- Tuesday, October 11, 2011, 9:24 AM United Therapeutics (UTHR) plans to offer $210M in notes due in 2016 and use the proceeds to buy back up to $212M in stock. Shares +1.7% premarket. Comment! [On the Move, Healthcare]
- Monday, October 10, 2011, 9:06 AM United Therapeutics (UTHR) lands a $45M contract from the NIH for studies related to the development of antiviral drugs. Shares +1.7% premarket. Comment! [Healthcare, On the Move]
- Thursday, September 15, 2011, 2:25 PM United Therapeutics (UTHR -0.9%) is down today after Goldman Sachs cut the shares to neutral on valuation, saying it sees greater upside potential and better relative value in Onyx (ONYX +4.6%). Comment! [Healthcare, On the Move]
-
Wednesday, August 24, 2011, 9:15 AM
Premarket gainers: AVGO +11%. RENN +12%. ATPG +10%. ELN +5%. CPST +4%.
Losers: PSUN -22%. UTHR -21%. HSOL -10%. TCAP -8%. AEO -7%. HGSI -7%. BUD -4%. TTM -4%. LPL -4%. BCS -4%. AUO -3%. STD -3%. Comment! [On the Move]
-
- View all 0 replies
-
Red Acre Investments
Sent out Red Acre's weekly review last night $ZIOP, $RPRX, $AMRN, $VVUS, $APPA, $UTHR, $THLD signup at http://www.redacre.com to get it. - View all 3 replies
-
Red Acre Investments: Thx for the kind words - Happy Easter to you as well.
-
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
Jim Van Meerten
$UTHR - 96% barchart technical buy signals - 9 new highs and up 8.52% in the last month - Relative Strength Index 71.79% - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
VFC's Stock House
Stock Watch Thursday - $BBRY, $AMRN, $GILD, $YMI, $TROV, $ONVO, $PFE, $UTHR - http://bit.ly/cAHZ42 - View all 0 replies
-
Jim Van Meerten
UTHR - 60% Barchart short term buy signal - $UTHR- 13 new highs in the last month - Relative Strength Index 61.64% - View all 0 replies
LATEST REPLIES
-
Red Acre Investments
Sent out Red Acre's weekly review last night $ZIOP, $RPRX, $AMRN, $VVUS, $APPA, $UTHR, $THLD signup at http://www.redacre.com to get it. - View all 3 replies
-
Red Acre Investments: Thx for the kind words - Happy Easter to you as well.
-
-
- View all 3 replies
-
Capitalist Bull: These are the stocks you want to pay attention to for possible setups in the near future.
-
Day Trader001: I get Volume alerts sent to me directly, I guess I just didn't get why you posted them. Thought I was missing something. Thanks
-
John Purdum
United Therapeutic Corp $UTHR chart shows high upside potential. Perfect timing of 50 Day/ 200 Day MA convergence. http://bit.ly/vH0Zfm - View all 2 replies
-
-
John Purdum: Previous earnings, forecasted earnings and sales. Somewhat difficult to calc for $UTHR because high earnings surprise 4 Q2, Q3.